BIOTECH ACQUISITION CO-CL A(NASDAQ:BIOT) stock News

BIOT Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Relativity Acquisition Corp.

Relativity Acquisition Corp. Announces the Public Filing of a Registration Statement on Form F-4 for Instinct Bio Technical Company Inc.

a month ago - By: Relativity Acquisition Corp.

Relativity Acquisition Corp. Announces the Public Filing of a Registration Statement on Form F-4 for Instinct Bio Technical Company Inc.

7 months ago - By: Relativity Acquisition Corp.

Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.

3 years ago - By: Biotech Acquisition Company

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

3 years ago - By: Blade Therapeutics, Inc.

Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

3 years ago - By: Biotech Acquisition Company

Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement

3 years ago - By: InvestorPlace - Mentions: MGLD TCRT OKTA EFOI ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

3 years ago - By: Biotech Acquisition Company

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

3 years ago - By: Biotech Acquisition Company

Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

3 years ago - By: Blade Therapeutics, Inc.

Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference

3 years ago - By: Blade Therapeutics, Inc.

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

3 years ago - By: Biotech Acquisition Company

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity

4 years ago - By: Biotech Acquisition Company

Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

4 years ago - By: Blade Therapeutics, Inc.

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

4 years ago - By: Blade Therapeutics, Inc.

Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

4 years ago - By: Blade Therapeutics, Inc.

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

4 years ago - By: Biotech Acquisition Company

BIOTECH ACQUISITION CO-CL A (BIOT) Stock News

BIOT Latest News, Press Relases and Analysis

Relativity Acquisition Corp. Announces the Public Filing of a Registration Statement on Form F-4 for Instinct Bio Technical Company Inc.

Relativity Acquisition Corp. Announces the Public Filing of a Registration Statement on Form F-4 for Instinct Bio Technical Company Inc.

Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity

Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement